非常规 T 细胞在泌尿系统肿瘤中：能抓住就抓住
Unconventional T cells in urological cancers: catch them if you can.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
E2F3/5/8 可作为人类膀胱癌的潜在预后生物标志物和新的治疗方向
英文原题：E2F3/5/8 serve as potential prognostic biomarkers and new therapeutic direction for human bladder cancer.
查看英文原题
E2F3/5/8 serve as potential prognostic biomarkers and new therapeutic direction for human bladder cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
E2F3/5/8 可能作为 BC 患者有前景的预后生物标志物和新的治疗方向。
研究思路结论见上方概要
结果
我们发现，BC患者中E2F1/2/3/4/5/7/8的mRNA表达水平显著高于对照组织。并且所有E2Fs的mRNA表达水平升高均与BC的肿瘤分期相关。生存分析显示，E2F3/5/8的mRNA表达水平升高与BC患者的总生存期（OS）显著相关。并且BC患者中E2Fs的基因改变与较短的总生存期（OS）和无进展生存期（PFS）相关。此外，我们发现E2F3/5/8的表达与TIL（肿瘤浸润淋巴细胞）（TILs）密切相关。
展开英文摘要原文
RESULTS
We found that the mRNA expression levels of E2F1/2/3/4/5/7/8 were significantly higher in BC patients than that of control tissues. And the increased mRNA expression levels of all E2Fs were associated with tumor stage of BC. The survival analysis revealed that the elevated mRNA expression levels of E2F3/5/8 were significantly correlated with the overall survival (OS) of BC patients. And the genetic changes of E2Fs in BC patients were associated with shorter overall survival (OS) and progression-free survival (PFS). In addition, we revealed that the E2F3/5/8 expressions were closely correlated with tumor-infiltrating lymphocytes (TILs).
CONCLUSIONS
E2F3/5/8 might serve as promising prognostic biomarkers and new therapeutic direction for BC patients.
论文信息
- 作者
- Gan Z、Abudurexiti A、Hu X、Chen W、Zhang N、Sang W
- 第一作者单位
- Surgery Department of Urology, The Third People's Hospital of Xinjiang Uyghur Autonomous Region, Urumqi, P.R. China.China
- 通讯作者单位
- Department of Pathology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, P.R. China.China
- 期刊
- Medicine2024 Jan 12
- 原文标识
- PubMed 38215110 · DOI 10.1097/MD.0000000000035722
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →